BETABiohacksAI is a research tool for informational purposes only. All outputs are computational hypothesis candidates — not confirmed mechanisms, not medical advice, and not a substitute for professional medical judgment. Independent experimental validation is always required.
BiohacksAI is an evolving scientific literature platform. New compounds and evidence are indexed continuously.
B
○

Losartan

An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.

1.0k+ PubMed studies analyzed · 783 RCTs · Evidence Score: 75

Research Domains

Losartan has been studied across 17 research domains including ❤️ Cardiovascular, 🫘 Kidney, 🔥 Metabolic, 🏋️ Muscle & Hypertrophy, 🦴 Bone & Joint. The primary research focus is ❤️ Cardiovascular with 75% of studies addressing this area.

Similar Compounds by Shared Targets

The following compounds share molecular targets with Losartan, based on binding affinity data from BindingDB and ChEMBL. Sorted by shared target overlap.

Irbesartan
14 shared targets
Valsartan
6 shared targets
Olmesartan
6 shared targets
Glyburide
10 shared targets
Rifamycins
6 shared targets
Rifamycins
6 shared targets
candesartan
13 shared targets
Ritonavir
12 shared targets
Buspirone
9 shared targets
Simvastatin
10 shared targets
Loading evidence profile...

This evidence profile for Losartan is generated deterministically from 1,000 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.

Data source: PubMed/MEDLINE (NLM). Corpus version: current. Patent pending (EVE-PAT-2026-001). © 2026 Organiq Sweden AB.